These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36632844)

  • 1. Invited Commentary: On the Mathematization of Epidemiology as a Socially Engaged Quantitative Science.
    Cartus AR; Marshall BDL
    Am J Epidemiol; 2023 May; 192(5):757-759. PubMed ID: 36632844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems.
    Bagley SM; Chavez L; Braciszewski JM; Akolsile M; Boudreau DM; Lapham G; Campbell CI; Bart G; Yarborough BJH; Samet JH; Saxon AJ; Rossom RC; Binswanger IA; Murphy MT; Glass JE; Bradley KA;
    Addict Sci Clin Pract; 2021 Jul; 16(1):46. PubMed ID: 34233750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Cascade of Care for responding to the opioid epidemic.
    Williams AR; Nunes EV; Bisaga A; Levin FR; Olfson M
    Am J Drug Alcohol Abuse; 2019; 45(1):1-10. PubMed ID: 30675818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
    Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.
    Jones KF; O'Reilly Jacob M; Spetz J; Hailer L; Tierney M
    J Nurs Scholarsh; 2023 May; 55(3):655-664. PubMed ID: 36624606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mobile service delivery in response to the opioid epidemic in Philadelphia.
    Stewart RE; Christian HP; Cardamone NC; Abrams C; Drob C; Mandell DS; Metzger D; Lowenstein M
    Addict Sci Clin Pract; 2023 Nov; 18(1):71. PubMed ID: 38031174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 11. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
    Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
    Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid use disorder treatment for people experiencing homelessness: A scoping review.
    McLaughlin MF; Li R; Carrero ND; Bain PA; Chatterjee A
    Drug Alcohol Depend; 2021 Jul; 224():108717. PubMed ID: 33985863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 15. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision.
    Kennedy-Hendricks A; Bandara S; Merritt S; Barry CL; Saloner B
    Drug Alcohol Depend; 2021 Sep; 226():108881. PubMed ID: 34218008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of a national training initiative to increase provider use of MAT to address the opioid epidemic.
    Levin FR; Bisaga A; Sullivan MA; Williams AR; Cates-Wessel K
    Am J Addict; 2016 Dec; 25(8):603-609. PubMed ID: 28051841
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.